Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$6.65 - $10.04 $36,468 - $55,059
-5,484 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$9.1 - $19.57 $49,904 - $107,321
5,484 New
5,484 $51,000
Q4 2020

Feb 12, 2021

SELL
$12.02 - $24.71 $721,200 - $1.48 Million
-60,000 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$4.25 - $14.19 $255,000 - $851,400
60,000 New
60,000 $853,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $109M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.